ATE417274T1 - Verfahren zur identifizierung von mit zap-70 wechselwirkenden molekülen und zur zap-70- reinigung - Google Patents

Verfahren zur identifizierung von mit zap-70 wechselwirkenden molekülen und zur zap-70- reinigung

Info

Publication number
ATE417274T1
ATE417274T1 AT06011409T AT06011409T ATE417274T1 AT E417274 T1 ATE417274 T1 AT E417274T1 AT 06011409 T AT06011409 T AT 06011409T AT 06011409 T AT06011409 T AT 06011409T AT E417274 T1 ATE417274 T1 AT E417274T1
Authority
AT
Austria
Prior art keywords
aminopyrido
zap
pyrimidine ligand
complex
phosphorylated zap
Prior art date
Application number
AT06011409T
Other languages
English (en)
Inventor
Ulrich Kruse
Nigel Ramsden
Gerard Drewes
Dirk Eberhard
Original Assignee
Cellzome Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ag filed Critical Cellzome Ag
Application granted granted Critical
Publication of ATE417274T1 publication Critical patent/ATE417274T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06011409T 2006-06-01 2006-06-01 Verfahren zur identifizierung von mit zap-70 wechselwirkenden molekülen und zur zap-70- reinigung ATE417274T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06011409A EP1862802B1 (de) 2006-06-01 2006-06-01 Verfahren zur Identifizierung von mit ZAP-70 wechselwirkenden Molekülen und zur ZAP-70-Reinigung

Publications (1)

Publication Number Publication Date
ATE417274T1 true ATE417274T1 (de) 2008-12-15

Family

ID=37075506

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06011409T ATE417274T1 (de) 2006-06-01 2006-06-01 Verfahren zur identifizierung von mit zap-70 wechselwirkenden molekülen und zur zap-70- reinigung

Country Status (11)

Country Link
US (1) US20120178180A1 (de)
EP (1) EP1862802B1 (de)
JP (1) JP4987970B2 (de)
CN (1) CN101490557B (de)
AT (1) ATE417274T1 (de)
AU (1) AU2007267291B2 (de)
CA (1) CA2653760A1 (de)
DE (1) DE602006004196D1 (de)
DK (1) DK1862802T3 (de)
ES (1) ES2318616T3 (de)
WO (1) WO2007137867A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5181908B2 (ja) * 2008-08-04 2013-04-10 株式会社島津製作所 質量分析データ解析装置
CA2758614A1 (en) 2009-04-14 2010-10-21 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
US20120172385A1 (en) 2009-09-11 2012-07-05 Richard John Harrison Ortho substituted pyrimidine compounds as jak inhibitors
CA2775009A1 (en) 2009-10-20 2011-04-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
WO2011134831A1 (en) 2010-04-30 2011-11-03 Cellzome Limited Pyrazole compounds as jak inhibitors
EP2574194B1 (de) * 2010-05-21 2017-10-11 University of Florida Research Foundation, Inc. Makrocyclische verbindungen zur verwendung in der behandlung von osteoporose
EP2588105A1 (de) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridine als tyk2-hemmer
US9040545B2 (en) 2010-08-20 2015-05-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
JP2014500254A (ja) 2010-11-09 2014-01-09 セルゾーム リミティッド Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
EP2736901A1 (de) 2011-07-28 2014-06-04 Cellzome Limited Heterocyclische pyrimidinanaloga als jak-inhibitoren
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
CN103874699A (zh) 2011-09-20 2014-06-18 赛尔佐姆有限公司 吡唑并[4,3-c]吡啶衍生物作为激酶抑制剂
CN104169272A (zh) 2011-12-23 2014-11-26 赛尔佐姆有限公司 作为激酶抑制剂的嘧啶-2,4-二胺衍生物
BR112014029310A2 (pt) 2012-05-24 2018-06-26 Cellzome Ltd análogos da pirimidina heterocíclica como inibidores da tyk2
CN108088998B (zh) * 2016-11-23 2019-12-27 四川大学华西医院 一种肺癌筛查试剂盒
KR20230104781A (ko) 2020-10-05 2023-07-10 인라이븐 테라퓨틱스, 인크. Bcr-abl 티로신 키나아제의 억제를 위한 5- 및 6-아자인돌 화합물
CN113030359A (zh) * 2021-01-28 2021-06-25 成都第一制药有限公司 一种益母草注射液中多种指标成分的检测方法及益母草注射液的质量控制方法
WO2022236319A1 (en) * 2021-05-07 2022-11-10 Enliven Therapeutics, Inc. Naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinases
WO2024159589A1 (zh) * 2023-01-31 2024-08-08 深圳市予一电子科技有限公司 滤光片及光子仪器

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6685938B1 (en) * 1998-05-29 2004-02-03 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
EP1250155B1 (de) * 1999-12-22 2008-04-16 The Scripps Research Institute Modulatoren und inhibitoren von angiogenese und vaskulärer durchlässigkeit
MXPA05009723A (es) * 2003-03-10 2006-02-17 Schering Corp Analisis de ligando.
ATE481134T1 (de) * 2004-01-21 2010-10-15 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
EP1794313B1 (de) * 2004-06-21 2013-05-15 Proteome Sciences Plc Screeningverfahren mit c-abl, fyn und syk in kombination mit tau-protein
EP1662259A1 (de) * 2004-11-25 2006-05-31 Cellzome Ag Verwendung von Eph Rezeptor-Inhibitoren zur Behandlung von neurodegenerativen Erkrankungen
AU2006247067B2 (en) * 2005-05-18 2012-06-07 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
PL1891446T3 (pl) * 2005-06-14 2013-08-30 Cellzome Gmbh Sposób identyfikacji nowych związków oddziałujących z enzymami
US20070105165A1 (en) * 2005-11-04 2007-05-10 Charles Goolsby Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
US8268809B2 (en) * 2006-09-05 2012-09-18 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
WO2008110508A1 (en) * 2007-03-09 2008-09-18 Glaxo Group Limited Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity

Also Published As

Publication number Publication date
EP1862802A1 (de) 2007-12-05
CN101490557B (zh) 2013-08-21
US20120178180A1 (en) 2012-07-12
AU2007267291B2 (en) 2013-09-12
JP2009539081A (ja) 2009-11-12
EP1862802B1 (de) 2008-12-10
CA2653760A1 (en) 2007-12-06
DK1862802T3 (da) 2009-04-14
CN101490557A (zh) 2009-07-22
DE602006004196D1 (de) 2009-01-22
ES2318616T3 (es) 2009-05-01
JP4987970B2 (ja) 2012-08-01
HK1115632A1 (en) 2008-12-05
AU2007267291A1 (en) 2007-12-06
WO2007137867A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
ATE417274T1 (de) Verfahren zur identifizierung von mit zap-70 wechselwirkenden molekülen und zur zap-70- reinigung
Timm et al. Assembly and purification of enzyme‐functionalized DNA origami structures
ATE414281T1 (de) Verfahren zur identifizierung von molekülen die mit pi3k interagieren und verfahren zur reinigung von pi3k
WO2001027624A3 (en) Compositions and methods for detecting protein modification and enzymatic activity
ATE489482T1 (de) Verfahren zur herstellung von hybridsubstraten mit dna und antikörpern sowie verwendungen davon
WO2003039483A3 (en) An enzyme-based system and sensor for measuring acetone
WO2006124644A3 (en) Protein and antibody profiling using small molecule microarrays
Cargnello et al. Phosphorylation of the eukaryotic translation initiation factor 4E-transporter (4E-T) by c-Jun N-terminal kinase promotes stress-dependent P-body assembly
WO2008076365A3 (en) Analyte sensors, methods for preparing and using such sensors, and methods of detecting analyte activity
Tikhomirova et al. ACE phenotyping in human heart
Lefkowitz et al. An electrophoretic method for the detection of chymotrypsin and trypsin activity directly in whole blood
CA2156743A1 (en) In-situ hybridization method using reca protein and reca protein having marker or ligand for use in said method
ATE545030T1 (de) Testverfahren für nukleinsäurebindendes protein auf biochipbasis
EP1243659A4 (de) Verfahren zur erkennung von zielnukleinsauren
Frischkorn et al. Transcriptional and proteomic choreography under phosphorus deficiency and re-supply in the N2 fixing cyanobacterium Trichodesmium erythraeum
DE602006006855D1 (de) Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb)
ATE404692T1 (de) Screening-verfahren zur identifizierung von tau- protein modulierenden substanzen.
ATE525462T1 (de) Proteomanalyseverfahren für phosphoryliertes protein
Pathan et al. Enzymes as indispensable markers in disease diagnosis
WO2005059163A3 (en) Methods, compositions, and kits for analysis of enzyme activity in cells
Salvi et al. Motif analysis of phosphosites discloses a potential prominent role of the Golgi casein kinase (GCK) in the generation of human plasma phospho-proteome
Galán et al. LC-MS/MS analysis of the dog serum phosphoproteome reveals novel and conserved phosphorylation sites: Phosphoprotein patterns in babesiosis caused by Babesia canis, a case study
ATE462001T1 (de) Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
SG148027A1 (en) Methods for identifying combinations of entities as therapeutics
DE602005018316D1 (de) Verfahren zum Nachweis einer Zielsubstanz unter Verwendung einer Nukleinsäuresonde

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1862802

Country of ref document: EP